KR20240004332A - 폰 빌레브란트 인자(vwf) 억제제 - Google Patents

폰 빌레브란트 인자(vwf) 억제제 Download PDF

Info

Publication number
KR20240004332A
KR20240004332A KR1020237036079A KR20237036079A KR20240004332A KR 20240004332 A KR20240004332 A KR 20240004332A KR 1020237036079 A KR1020237036079 A KR 1020237036079A KR 20237036079 A KR20237036079 A KR 20237036079A KR 20240004332 A KR20240004332 A KR 20240004332A
Authority
KR
South Korea
Prior art keywords
seq
chain variable
antibody
antigen
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237036079A
Other languages
English (en)
Korean (ko)
Inventor
나딘 클레모
알란 루이스
톰 맥키넌
Original Assignee
아이피2아이피오 이노베이션스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이피2아이피오 이노베이션스 리미티드 filed Critical 아이피2아이피오 이노베이션스 리미티드
Publication of KR20240004332A publication Critical patent/KR20240004332A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/755Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237036079A 2021-04-20 2022-04-20 폰 빌레브란트 인자(vwf) 억제제 Pending KR20240004332A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2105625.4A GB202105625D0 (en) 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors
GB2105625.4 2021-04-20
PCT/GB2022/050989 WO2022223966A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors

Publications (1)

Publication Number Publication Date
KR20240004332A true KR20240004332A (ko) 2024-01-11

Family

ID=76377797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036079A Pending KR20240004332A (ko) 2021-04-20 2022-04-20 폰 빌레브란트 인자(vwf) 억제제

Country Status (12)

Country Link
US (1) US20240228660A1 (https=)
EP (1) EP4326778A1 (https=)
JP (1) JP2024514708A (https=)
KR (1) KR20240004332A (https=)
CN (1) CN117597367A (https=)
AU (1) AU2022262695A1 (https=)
BR (1) BR112023021631A2 (https=)
CA (1) CA3214716A1 (https=)
GB (1) GB202105625D0 (https=)
IL (1) IL307441A (https=)
MX (1) MX2023012391A (https=)
WO (1) WO2022223966A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202215432D0 (en) * 2022-10-19 2022-11-30 Ip2Ipo Innovations Ltd Von Willebrand factor (VWF) antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2543678A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis

Also Published As

Publication number Publication date
JP2024514708A (ja) 2024-04-02
US20240228660A1 (en) 2024-07-11
MX2023012391A (es) 2024-02-02
CN117597367A (zh) 2024-02-23
IL307441A (en) 2023-12-01
EP4326778A1 (en) 2024-02-28
WO2022223966A1 (en) 2022-10-27
CA3214716A1 (en) 2022-10-27
GB202105625D0 (en) 2021-06-02
AU2022262695A1 (en) 2023-10-05
BR112023021631A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
DK2427212T3 (en) ANTI-CD100 ANTIBODIES AND PROCEDURES FOR USE THEREOF
AU2008330125B2 (en) Wise binding antibodies and epitopes
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
TW201132353A (en) WISE binding agents and epitopes
HUE028361T2 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
KR20220121808A (ko) 항-pd-l1/항-b7-h3 다중특이적 항체 및 이의 용도
CA3150726A1 (en) Anti-alpha-synuclein antibodies and methods of use thereof
US20230357387A1 (en) Zip12 antibody
KR20240004332A (ko) 폰 빌레브란트 인자(vwf) 억제제
WO2024084214A1 (en) Von willebrand factor (vwf) antibody
CN112969715A (zh) 一种抗cd47抗原结合蛋白及其应用
US12448441B2 (en) ZIP12 antibody
JP7690612B2 (ja) 抗masp-2抗体及びその使用
WO2025172587A1 (en) Binding constructs
WO2025172588A1 (en) Bispecific constructs directed against fap and ltbr
JP2025504543A (ja) Btlaに対する抗体及びその使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231020

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250331

Comment text: Request for Examination of Application